Food Allergy Clinical Trials

This study will explore potential links between atopic dermatitis and food allergy to determine unique biochemical or genetic identifiers useful for diagnosing and treatments in the future. [HUM00235532]

For more information, visit U-M Health Research Study page 

PI: Charles Schuler IV, MD
 

A Phase I Randomized, Quadruple-blinded, Placebo-controlled, Single-ascending and Multiple Dose Study to Evaluate the Safety, Local Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Exploratory Clinical Activity of MY006 in Healthy Volunteers and Adolescent and Adult Patients with Peanut Allergy [HUM00286332]

PI: Ian Slack, MD

For more information, visit U-M Health Research Study page 

A study to identify biomarkers and investigate mechanisms of food anaphylaxis. An observational and bio-sampling study of patients undergoing oral food challenges during routine clinical care or on research protocols for clinical trials. [HUM00165471]

PI: Charles Schuler IV, MD

The purpose of this post-market study is to certify that an extensively broken-down milk protein based infant formula is hypoallergenic (designed to reduce or minimize the possibility of an allergic reaction) in infants and children with a confirmed cow’s milk allergy. [HUM00259595] 

PI: Ian Slack, MD

For more information, visit U-M Health Research Study page 

A Phase IV Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients with allergic reactions after Oral Food Challenge or Allergen Immunotherapy (EPI R01) [HUM00272780]

PI: Ian Slack, MD

Phase I Safety Study of MOON101 for the Treatment of Peanut Allergy [HUM00279902]

PI: Ian Slack, MD

For more information, visit U-M Health Research Study page 

A 52-week multicenter, randomized, double-blind, placebo-controlled Phase 3 study to assess efficacy and safety of remibrutinib (LOU064) in adult and adolescent participants with IgE-mediated food allergy [HUM00278418]

PI: Ian Slack, MD

Efficacy of Tezepelumab in Peanut Oral Immunotherapy: a Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial [HUM00271618]

PI: Ian Slack, MD

Study of Oral Food Challenge Biomarkers [HUM00287633]

PI: James Baker Jr., MD

Phase 3 trial in peanut-allergic children ages 4 – 7 is a 12-month study evaluating the efficacy and safety of the Viaskin Peanut Patch in more than 600 subjects worldwide. [HUM00229249]

PI: Kelly O’Shea, MD

A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-through 3-year-old Children with Peanut Allergy [HUM00275174]

PI: Ian Slack, MD

Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of RPT904 as Monotherapy in Participants with IGE-mediated Food Allergy [HUM00283688]

PI: Ian Slack, MD